Status:

COMPLETED

Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine

Lead Sponsor:

Allergan

Conditions:

Chronic Migraine

Eligibility:

All Genders

18-80 years

Phase:

PHASE3

Brief Summary

This study evaluated the efficacy, safety and tolerability of atogepant in participants with chronic migraine. This study included a 12-week treatment period.

Eligibility Criteria

Inclusion

  • At least a 1-year history of chronic migraine (CM) consistent with a diagnosis according to the International Classification of Headache Disorders, 3rd Edition (ICHD-3), 2018
  • Age of the participant at the time of migraine onset \< 50 years
  • Confirmation of headache/migraine headache day frequency as follows:
  • History of, on average, ≥ 15 headache days per month in the 3 months prior to Visit 1 in the opinion of the investigator AND
  • \>=15 headache days during the 4-week screening/baseline period per the electronic diary (eDiary) AND
  • \>=8 days during the 4-week screening/baseline period that qualify as being a migraine day per the eDiary
  • Participants must be using a medically acceptable and effective method of birth control during the course of the entire study

Exclusion

  • Has a history of migraine, accompanied by diplopia or decreased level of consciousness, or retinal migraine
  • Has a current diagnosis of new persistent daily headache, trigeminal autonomic cephalgia (eg, cluster headache), or painful cranial neuropathy
  • History of an inadequate response to \> 4 medications (2 of which have different mechanisms of action) prescribed for the prevention of migraine
  • Woman is pregnant, planning to become pregnant during the course of the study, or currently lactating. Women of childbearing potential must have a negative urine pregnancy test at Visit 1 and Visit 2.

Key Trial Info

Start Date :

March 11 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 20 2022

Estimated Enrollment :

778 Patients enrolled

Trial Details

Trial ID

NCT03855137

Start Date

March 11 2019

End Date

January 20 2022

Last Update

February 14 2023

Active Locations (150)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 38 (150 locations)

1

Barrow Neuro Institute /ID# 236776

Phoenix, Arizona, United States, 85013

2

Baptist Health Center for Clinical Research /ID# 237361

Little Rock, Arkansas, United States, 72205

3

California Headache and Balance Center /ID# 236246

Fresno, California, United States, 93720

4

Wr-Pri Llc /Id# 236008

Los Alamitos, California, United States, 90720